Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.
IM-12 GMP 是 GMP 级别的 IM-12 (MS-X78045),GMP 级别的小分子可用作细胞疗法中的辅助试剂,而 IM-12 是一种口服有效的抗炎剂,可靶向抑制 NF-κB 和 STAT3 信号通路,通过抑制 GSK3β 激活 Wnt 信号并促进 β-catenin 的核转位,同时阻断 p210BCR/ABL 酪氨酸激酶活性,降低 IL-6、IL-17、NO、前列腺素 E2、iNOS 和 COX-2 的水平,诱导 ER 应激、Ca2+ 释放、自噬 (autophagy) 与凋亡 (apoptosis),且对热敏感,不会在耐 IM 的 p210BCR/ABLT315I 突变细胞中诱导自噬,还是用于原始多能干细胞研究的 5iLA 培养基的组分之一,并已被应用于对 Carrageenan (MS-L60716) 诱导的后爪水肿、TNBS 诱导的结肠炎以及急性和慢性髓系白血病的相关研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号